Having -c(=x)-, Wherein X Is Chalcogen, Attached Indirectly To Ring Carbon Of The Five-membered Hetero Ring By An Acyclic Carbon Or Acyclic Carbon Chain (e.g., Indole-3-acetic Acid, Etc.) Patents (Class 548/494)
Abstract: The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, eczema, urticaria diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.
Type:
Application
Filed:
January 22, 2009
Publication date:
July 9, 2009
Inventors:
Zhaoxia YANG, Stephan REILING, Thaddeus NIEDUZAK, Rose M. MATHEW, Sharon JACKSON, Keith John HARRIS
Abstract: The present invention provides a compound of the general formula (I), wherein X is the connection between the CO-hydrazine and the NR1-oxalic acid or ester group, and uses and synthesis methods. These compounds represent amino acid derivatives, wherein the amine group is turned into an acidic group by the oxalic acid group and the carboxylic acid is turned into an amine functionality by the hydrazine group; as well as peptidomimetics comprising the compound and methods for their synthesis.
Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.
Type:
Grant
Filed:
February 27, 2006
Date of Patent:
April 14, 2009
Assignee:
TetraLogic Pharmaceuticals Corporation
Inventors:
Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
Abstract: Methods for preferentially hydrolyzing one stereoisomer of an isoxazoline diester over another, as well as an enzyme for facilitating the preferential hydrolysis are provided. Also provided are methods for providing mixtures of (RR) and (RS) monatin as well as (SS) and (SR) monatin, which methods can include the step of stereoselectively hydrolyzing an isoxazoline diester.
Type:
Application
Filed:
October 1, 2007
Publication date:
April 2, 2009
Inventors:
Dean Brady, Lucia H. Steenkamp, Amanda Louise Rousseau, Subash Buddoo, Paul A. Steenkamp
Abstract: [Object] To provide a compound having prostaglandin production-suppressing action and leukotriene production-suppressing action. [Means for Solution] A compound represented by the formula (I): [In the formula, represents a single bond, or a double bond, Link represents a single bond, or a saturated or unsaturated straight hydrocarbon having 1 or 2 carbon atoms, W represents a single bond, oxygen atom, sulfur atom, N(Rw) etc., Rw represents hydrogen atom, an alkyl group having 1 to 8 carbon atoms etc, Rs represents -D-Rx etc., D represents a single bond, oxygen atom, sulfur atom etc., Rx represents a linear or branched saturated alkyl group having 3 to 8 carbon atoms etc., one of V1 and V2 represents Zx, and the other represents AR, Zx represents hydrogen atom, a linear or branched saturated alkyl group having 1 to 4 carbon atoms etc.
Abstract: A process for the preparation of indole derivatives of formula (I): which are useful as intermediates in the preparation of pharmaceutically active compounds.
Type:
Application
Filed:
June 25, 2008
Publication date:
January 8, 2009
Inventors:
Stephan Bachmann, Philippe Pflieger, Goesta Rimmler, Michelangelo Scalone
Abstract: The present invention relates to N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof wherein n is 2 or 3; and R1 represents or pharmaceutically acceptable salts thereof, to novel processes for preparing the same, to use thereof as anti-allergic, anti-anaphylactic, anti-inflammatory and hypolipidemic agents as well as to a pharmaceutical composition comprising the indicated compounds in an efficient amount and to a method for treating allergic and inflammatory diseases and lipid metabolism disorders: bronchial asthma, allergic rhinitis, pollinoses, seasonal and year-round rhinitis, allergic pneumonitis, atopic dermatitis, psoriasis, urticaria, allergic (including anaphylactic) reactions to insect stings and medicaments, cold allergy, allergic conjunctivitis, atherosclerosis, obesity, ischemic heart and cerebral disease, myocardial infarction and stroke.
Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.
Type:
Grant
Filed:
July 15, 2005
Date of Patent:
November 25, 2008
Assignee:
Tetralogic Pharmaceuticals Corporation
Inventors:
Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
Abstract: The invention relates to a group of novel indole compounds of Formula (I): wherein: R1, R2, R4, R6, R6a, R7, R8, R9, R10, and A are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
Type:
Grant
Filed:
August 18, 2003
Date of Patent:
November 11, 2008
Assignee:
AstraZeneca AB
Inventors:
Francis Thomas Boyle, Robert Davies, Zbigniew Matusiak, Michael Wardleworth
Abstract: A novel crystalline form of Fluvastatin sodium hydrate is described, referred to hereinafter as polymorphic Form G. Furthermore, processes for the preparation of this crystalline form and pharmaceutical compositions comprising this crystalline form are reported.
Type:
Grant
Filed:
October 6, 2004
Date of Patent:
October 7, 2008
Assignee:
Ciba Specialty Chemicals Corp.
Inventors:
Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz
Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.
Abstract: The invention provides compounds of formula I wherein n, A, R, R?, R?, Ro, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.
Abstract: This invention provides compounds of the formula: wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
Type:
Grant
Filed:
March 29, 2006
Date of Patent:
May 6, 2008
Assignee:
Wyeth
Inventors:
Hassan Mahmound Elokdah, Geraldine Ruth McFarlane, David Zenan Li, Lee Dalton Jennings, David LeRoy Crandall
Abstract: The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula: useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.
Type:
Grant
Filed:
May 26, 2006
Date of Patent:
April 29, 2008
Assignee:
Enobia Pharma
Inventors:
Denis Gravel, Elaref S. Ratemi, Mostafa Hatam, Guy Boileau, Philippe Crine, Isabelle Lemire
Abstract: Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer.
Type:
Grant
Filed:
November 14, 2005
Date of Patent:
April 29, 2008
Assignee:
Bristol-Myers Squibb Company
Inventors:
Philip M. Sher, Gang Wu, Wei Meng, Alexandra A. Nirschl, William N. Washburn, Terry Stouch
Abstract: Use is disclosed of (a) an AlDH-inhibitory amount of a Trp metabolite, or an analogue or derivative thereof or (b) a bioprecursor thereof, or (c) a potentiator of (a) and/or (b), in the preparation of a medicament for treating alcoholism and/or alcohol dependence.
Abstract: Cyclohexylurea compounds corresponding to formula I a method for producing them, pharmaceutical compositions containing them, and the use of such compounds as pharmaceutically active agents with nociceptin/ORL1 receptor system activity for treating pain or other conditions associated with the nociceptin/ORL1 receptor system.
Abstract: The present invention relates to a process for producing efficiently glutamic acid derivatives (including salts thereof) such as monatin by converting a substituted ?-keto acid of formula (1) into a glutamic acid derivative of formula (2) in the presence of an enzyme catalyzing conversion of the same
Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
Type:
Grant
Filed:
April 1, 2005
Date of Patent:
October 30, 2007
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
James C. Lanter, Zhihua Sui, James J. Fiordeliso, Weiqin Jiang, Xuqing Zhang
Abstract: The present invention relates to novel anhydrous amorphous forms of bis[(E)[4-(4-fluorophenyl)isopropyl[methyl(methylsulfonyl)amino]pyrimidinyl](3R,5S)-3,5-dihydroxyhept enoic acid]calcium salt (rosuvastatin calcium), (±)7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)3,5-dihydroxy heptenoic acid monosodium salt (fluvastatin sodium) and bis[(E)-3,5-dihydroxy-7-[4?-(4?-fluorophenyl)-2?-cyclopropyl-quinolin-3?-hept-6-enoic acid]calcium salt (pitavastatin calcium), to processes for their preparation, to pharmaceutical compositions containing them and to methods of treatment using the same. The rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium obtained are known valuable agents useful in treating hyperlipidemia and hypercholestrolemia.
Abstract: Mono-acylated o-phenylendiamines derivatives of formula I wherein X and R are as described herein, have been found useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.
Type:
Grant
Filed:
February 3, 2004
Date of Patent:
April 24, 2007
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Georg Fertig, Frank Herting, Manfred Kubbies, Anja Limberg, Ulrike Reiff, Michael Weidner
Abstract: The invention relates to derivatives of indole-3-carboxamide having general formula (I): wherein: R1 represents a C3–C10 alkyl, a C5–C10 carbocyclic radical that is unsubstituted or substituted one or more times with a methyl group; R2 represents a hydrogen atom or a (C1–C4)alkyl group; R3 represents a halogen atom or a (C1–C4)alkyl group; R4 represents a hydrogen or halogen atom or a (C1–C4)alkyl group; R5 represents a (C1–C4)alkyl group or a trifluoromethyl; X represents a sulfur atom, an —NHSO2— group or an —SO2— group; and n is equal to 2 or 3. The invention also relates to a method of preparing the aforementioned derivatives and to the application of same in therapeutics.
Type:
Grant
Filed:
May 26, 2005
Date of Patent:
April 10, 2007
Assignee:
Sanofi-aventis
Inventors:
Francis Barth, Mireille Rinaldi-Carmona, Claude Vernhet
Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.
Type:
Grant
Filed:
July 16, 2004
Date of Patent:
April 10, 2007
Assignee:
Plexxikon, Inc.
Inventors:
James Arnold, Dean R. Artis, Clarence R. Hurt, Prabha N. Ibrahim, Heike Krupka, Jack Lin, Michael V. Milburn, Weiru Wang, Chao Zhang
Abstract: The invention is concerned with novel mandelic acid derivatives of formula (I) wherein R1 to R10, X and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor.
Type:
Grant
Filed:
November 21, 2003
Date of Patent:
October 31, 2006
Assignee:
Hoffmann-La Roche Inc.
Inventors:
David William Banner, Luca Claudio Gobbi, Katrin Groebke Zbinden, Ulrike Obst, Christoph Martin Stahl
Abstract: Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R1, R2, R3, and R4 are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus.
Abstract: Methods for identifying MarR family inhibiting compounds are described. The methods include the use of computer aided rational based drug design programs and three dimensional structures of MarR family polypeptides.
Type:
Grant
Filed:
July 15, 2002
Date of Patent:
July 11, 2006
Assignee:
Paratek Pharmaceuticals, Inc.
Inventors:
Michael N. Alekshun, Stuart B. Levy, Brent L. Podlogar, Roger Frechette
Abstract: This invention provides compounds of the formula: wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
Type:
Grant
Filed:
June 18, 2002
Date of Patent:
July 11, 2006
Assignee:
Wyeth
Inventors:
Hassan Mahmoud Elokdah, Geraldine Ruth McFarlane, David Zenan Li, Lee D. Jennings, David LeRoy Crandall
Abstract: The present invention is directed toward substituted hydroxyethylene compounds of formula (XII) useful in treating Alzheimer's disease and other similar diseases.
Type:
Grant
Filed:
May 18, 2004
Date of Patent:
April 18, 2006
Assignee:
Elan Pharmaceuticals, Inc.
Inventors:
Roy Hom, Shumeye S. Mamo, Jay Tung, Andrea Gailunas, Varghese John, Lawrence Y. Fang
Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
Type:
Grant
Filed:
March 5, 2004
Date of Patent:
April 11, 2006
Assignee:
G.D. Searle & Co.
Inventors:
John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, Kathryn L. Reed, Ko-Chung Lin, John Nicholas Freskos, Michael Clare, Donald Joseph Rogier, Jr., Robert M. Heintz, Michael L. Vazquez, Richard A. Mueller
Abstract: A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
Type:
Grant
Filed:
July 30, 2003
Date of Patent:
September 6, 2005
Assignee:
Eli Lilly and Company
Inventors:
Richard Waltz Harper, Ho-Shen Lin, Michael Enrico Richett
Abstract: What is described are derivatives of benzoylcyclohexanediones of the formula (I) and their use as herbicides. In this formula (I), R1a, R1b, R1c, R2, R3, R4 and R5 denote various radicals, X1 is a bridging atom, X2 is a carbon chain and X3 is a chalcogen atom or an oximino radical.
Type:
Grant
Filed:
April 8, 2003
Date of Patent:
August 16, 2005
Assignee:
Bayer CropScience GmbH
Inventors:
Thomas Seitz, Andreas van Almsick, Lothar Willms, Monika H. Schmitt, Thomas Auler, Hermann Bieringer, Hubert Menne
Abstract: The invention concerns novel mikanolide derivatives, their preparation method and their therapeutic uses, in particular as anti-cancer and anti-viral agents.
Type:
Grant
Filed:
January 11, 2002
Date of Patent:
May 3, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Abstract: Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomers of fluvastatin, referred to as polymorphic Forms A, B1, B2, C, D and E, processes for the preparation of these crystalline forms and pharmaceutical compositions comprising them are disclosed.
Type:
Grant
Filed:
October 23, 2001
Date of Patent:
February 22, 2005
Assignee:
Ciba Specialty Chemicals Corporation
Inventors:
Paul Adriaan Van Der Schaaf, Heinz Wolleb, Annemarie Wolleb, Claudia Marcolli, Martin Szelagiewicz, Andreas Burkhard, Beat Freiermuth
Abstract: Compounds according to the following Formula (I): are effective in treating conditions characterized by excess metalloprotease activity.
Type:
Grant
Filed:
September 18, 2002
Date of Patent:
February 8, 2005
Assignee:
The Procter & Gamble Company
Inventors:
Stanislaw Pikul, Katherine King Mieling, Kelly Michelle Solinsky, Biswanath De, Neil Gregory Almstead, Michael George Natchus, Glen Edward Mieling
Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis.
Abstract: A process for the preparation of a compound of formula (IV), or an ester or a salt thereof comprising 1) reacting a compound of formula (I), (wherein Ra represents C1-4 alkyl, Rb represents C1-4 alkyl and Rc represents C1-6 alkyl) with a compound of formula X2C=0 (wherein each X independently represents a leaving group) to give a compound of formula (II), (wherein Ra, Rb and Rc are as hereinbefore defined); and 2) reacting said compound of formula (II) with a compound of formula (III) (wherein Rd represents hydrogen or a protecting group).
Abstract: The present invention ralates to compounds of formula (I): wherein R is hydrogen (H) or C1-6 alkyl; and X is defined such that —NH—(X)—COOH is the residue of an amino acid, which amino acid may itself optionally be substituted at any pendant amino group thereof by a residue of a carboxylic acid or a derivative thereof; or a salt thereof. The use of these compounds, in particular as potential anti-inflammatory and immunomodulatory drugs, and their preparation are described.
Abstract: Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.
Type:
Grant
Filed:
August 30, 2002
Date of Patent:
November 30, 2004
Assignee:
Wyeth
Inventors:
Frances Christy Nelson, Arie Zask, James Ming Chen, Dominick Mobilio, Ramaswamy Nilakantan
Abstract: Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.
Type:
Application
Filed:
April 27, 2004
Publication date:
November 25, 2004
Applicant:
The Institute for Pharmaceutical Discovery LLC
Inventors:
Michael Lee Jones, David Gunn, John Howar Jones, Michael C. Van Zandt
Abstract: Novel compounds of formula
wherein the substituents are defined as in the specification and are useful for inhibiting neuronal NO synthase or inducible NO synthase as well as inhibiting lipidic peroxidation.
Type:
Grant
Filed:
October 31, 2002
Date of Patent:
November 23, 2004
Assignee:
Societe de Conseils de Recherchet et E'Applications
Scientifiques (S.C.R.A.S.)
Inventors:
Serge Auvin, Jeremiah Harnett, Pierre-Etienne Chabrier de Lassauniere
Abstract: A desired N-acylamino acid and a salt thereof can be produced efficiently and conveniently, almost without leaving any odor in the object product, by reacting amino acid or a salt thereof with a fatty acid halide under basic conditions in the presence of a phosphorus compound.
Abstract: Intermediates A, which are important in the whole synthesis of vindoline; and a method of synthesizing intermediates respectively represented by the general formulae B and C. By the method, the target intermediates are effectively synthesized with satisfactory reproducibility. This synthesis method is especially suitable for mass production. General formula A General formula B General formula C.
Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
Type:
Application
Filed:
April 16, 2004
Publication date:
November 11, 2004
Inventors:
Nobert Hofgen, Hildegard Kuss, Matthias Olbrich, Ute Egerland, Chris Rundfeldt, Karin Steinike, Rudolf Schindler
Abstract: There is described the use of indoline derivatives of formula
wherein
R1 is hydrogen; C1-C5alkyl; C1-C18alkoxy; or halogen;
R2 is C1-C8alkyl; C5-C7cycloalkyl; C6-C10aryl;
R3 is C1-C18alkyl or a radical of formula (1a)
R4 is hydrogen; or a radical of formula
R5 is
C1-C18alkoxy; or a radical of formula
R6 and R7 are each independently of the other hydrogen; or C1-C5alkyl;
R8 is hydrogen; C1-C5alkyl; C5-C7cycloalkyl; phenyl; phenyl-C1-C3alkyl;
R9 is C1-C18alkyl;
X is halogen; a radical of formula (1c)
and
n is 0; or 1,
as light-protective agents.
Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.